×
About 10,798 results

BRIEF-Goldman Sachs Chief Warns New York City's Future ‘Not Guaranteed’ - FT
https://www.reuters.com/article/brief-goldman-sachs-chief-warns-new-york/brief-goldman-sachs-chief-warns-new-york-citys-future-not-guaranteed-ft-idUSFWN2SL17A

Nov 30th, 2021 - Nov 30 (Reuters) - * GOLDMAN SACHS CHIEF WARNS NEW YORK CITY’S FUTURE ‘NOT GUARANTEED’ - FT * DAVID SOLOMON SAYS HIGH TAXES THREATEN NEW YORK’S STATUS AS GLOBAL BUSINESS DESTINATION- FT Further company coverage:

BRIEF-Astrazeneca Says Lynparza Granted FDA Priority Review For Olympia
https://www.reuters.com/article/brief-astrazeneca-says-lynparza-granted/brief-astrazeneca-says-lynparza-granted-fda-priority-review-for-olympia-idUSASN001XX2

Nov 30th, 2021 - Nov 30 (Reuters) - AstraZeneca PLC: * ASTRAZENECA PLC - LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIA * ASTRAZENECA - LYNPARZA GRANTED PRIORITY REVIEW IN US FOR BRCA-MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER Source text for Eikon: Further company coverage:

BRIEF-Novavax Inc - Has Already Initiated Development Of A New Recombinant Spike Protein Based On The Known Genetic Sequence Of B.1.1.529
https://www.reuters.com/article/brief-novavax-inc-has-already-initiated/brief-novavax-inc-has-already-initiated-development-of-a-new-recombinant-spike-protein-based-on-the-known-genetic-sequence-of-b-1-1-529-idUSFWN2SH0F9

Nov 26th, 2021 - Nov 26 (Reuters) - Novavax Inc: * NOVAVAX INC - HAS ALREADY INITIATED DEVELOPMENT OF A NEW RECOMBINANT SPIKE PROTEIN BASED ON THE KNOWN GENETIC SEQUENCE OF B.1.1.529 * NOVAVAX - WILL HAVE NEW RECOMBINANT SPIKE PROTEIN BASED ON KNOWN GENETIC SEQUENCE OF B.1.1.529 READY FOR TESTING, MANUFACTURING WITHIN NEXT FEW WEEKS * NOVAVAX - RECENT DATA FROM PHASE 2 TRIAL LEAD US TO BELIEVE THAT OUR VACCINE ...

BRIEF-U.S. FDA Publishes Briefing Documents On Merck's Covid-19 Pill
https://www.reuters.com/article/brief-us-fda-publishes-briefing-document/brief-u-s-fda-publishes-briefing-documents-on-mercks-covid-19-pill-idUSFWN2SH0H9

Nov 26th, 2021 - Nov 26 (Reuters) - U.S. Food and Drug Administration: * U.S. FDA PUBLISHES BRIEFING DOCUMENTS ON MERCK & CO INC'S COVID-19 PILL Source text: (bit.ly/311Toua) Further company coverage:

BRIEF-Alibaba Empowers Business Units To Be More Agile As Challenges Mount - WSJ
https://www.reuters.com/article/brief-alibaba-empowers-business-units-to/brief-alibaba-empowers-business-units-to-be-more-agile-as-challenges-mount-wsj-idUSFWN2SG0U0

Nov 26th, 2021 - Nov 26 (Reuters) - * ALIBABA EMPOWERS BUSINESS UNITS TO BE MORE AGILE AS CHALLENGES MOUNT - WSJ * ALIBABA’S CEO DANIEL ZHANG IS DEVOLVING POWER TO UNIT PRESIDENTS AS COMPETITION GROWS AND BIG PLATFORMS COME UNDER PRESSURE IN CHINA - WSJ * CHANGES MAY PAVE THE WAY FOR ALIBABA TO HIVE OFF SMALLER SUBSIDIARIES AND SEEK SEPARATE LISTINGS FOR THEM- WSJ Further company coverage:

BRIEF-Google, On Update On Privacy Sandbox Commitments, Says Offered To Appoint Independent Monitoring Trustee - Blog
https://www.reuters.com/article/brief-google-on-update-on-privacy-sandbo/brief-google-on-update-on-privacy-sandbox-commitments-says-offered-to-appoint-independent-monitoring-trustee-blog-idUSFWN2SH08N

Nov 26th, 2021 - Nov 26 (Reuters) - Alphabet Inc: * GOOGLE, ON UPDATE ON PRIVACY SANDBOX COMMITMENTS, SAYS OFFERED TO APPOINT INDEPENDENT MONITORING TRUSTEE - BLOG * GOOGLE - OFFERED CMA MORE EXTENSIVE TESTING COMMITMENTS, ALONG WITH MORE TRANSPARENT PROCESS TO TAKE MARKET FEEDBACK ON THE PRIVACY SANDBOX PROPOSALS * GOOGLE ON PRIVACY SANDBOX-CO NOT TO USE GOOGLE FIRST-PARTY PERSONAL DATA TO TRACK USERS FOR TARG...

BRIEF-EMA Approves Comirnaty COVID-19 Vaccine For Children Aged 5 To 11
https://www.reuters.com/article/brief-ema-approves-comirnaty-covid-19-va/brief-ema-approves-comirnaty-covid-19-vaccine-for-children-aged-5-to-11-idUSFWN2SG0JN

Nov 25th, 2021 - Nov 25 (Reuters) - European Medicines Agency: * EMA ON PFIZER COVID-19 VACCINE: COMIRNATY COVID-19 VACCINE: EMA RECOMMENDS APPROVAL FOR CHILDREN AGED 5 TO 11 * EMA SAYS THE VACCINE, DEVELOPED BY BIONTECH AND PFIZER, IS ALREADY APPROVED FOR USE IN ADULTS AND CHILDREN AGED 12 AND ABOVE. * EMA SAYS IN CHILDREN FROM 5 TO 11 YEARS OF AGE, DOSE OF COMIRNATY WILL BE LOWER THAN THAT USED IN PEOPLE AGED...

BRIEF-S&P Revises Outlook On Intesa Sanpaolo To Positive From Stable
https://www.reuters.com/article/brief-sp-revises-outlook-on-intesa-sanpa/brief-sp-revises-outlook-on-intesa-sanpaolo-to-positive-from-stable-idUSFWN2SE118

Nov 23rd, 2021 - Nov 23 (Reuters) - Intesa Sanpaolo SpA: * S&P GLOBAL RATINGS REVISES OUTLOOK FROM STABLE TO POSITIVE AND AFFIRMS RATINGS Further company coverage: (Gdansk Newsroom)

BRIEF-Intesa Sanpaolo, Iren Sign Deal To Sell Tax Credits For Up To EUR 170 Mln
https://www.reuters.com/article/brief-intesa-sanpaolo-iren-sign-deal-to/brief-intesa-sanpaolo-iren-sign-deal-to-sell-tax-credits-for-up-to-eur-170-mln-idUSFWN2SE0HW

Nov 23rd, 2021 - Nov 23 (Reuters) - Intesa Sanpaolo SpA: * INTESA SANPAOLO AND IREN SIGN AGREEMENT FOR SALE OF TAX CREDITS UP TO 170 MILLION EUROS Further company coverage: (Gdansk Newsroom)

BRIEF-U.S. FTC Privacy Probe Of Amazon Ring Puts Khan's Agenda In The Spotlight - The Information
https://www.reuters.com/article/brief-us-ftc-privacy-probe-of-amazon-rin/brief-u-s-ftc-privacy-probe-of-amazon-ring-puts-khans-agenda-in-the-spotlight-the-information-idUSFWN2SD1I1

Nov 22nd, 2021 - Nov 22 (Reuters) - * FTC PRIVACY PROBE OF AMAZON RING PUTS KHAN’S AGENDA IN THE SPOTLIGHT - THE INFORMATION

BRIEF-Biden Administration Looks To Expand Access To COVID-19 Antiviral Pills - WSJ
https://www.reuters.com/article/brief-biden-administration-looks-to-expa/brief-biden-administration-looks-to-expand-access-to-covid-19-antiviral-pills-wsj-idUSFWN2SA0TP

Nov 19th, 2021 - Nov 19 (Reuters) - * BIDEN ADMINISTRATION LOOKS TO EXPAND ACCESS TO COVID-19 ANTIVIRAL PILLS - WSJ * OFFICIALS ARE REVIEWING WHETHER PAXLOVID, PFIZER’S ORAL COVID DRUG AWAITING APPROVAL, CAN BE MADE WIDELY AVAILABLE ON THE COMMERCIAL MARKET - WSJ

BRIEF-J&J Says Confident About Delivering A Billion Covid-19 Vaccine Doses In 2022
https://www.reuters.com/article/brief-jj-says-confident-about-delivering/brief-jj-says-confident-about-delivering-a-billion-covid-19-vaccine-doses-in-2022-idUSFWN2S91CV

Nov 18th, 2021 - Nov 18 (Reuters) - Johnson & Johnson: * J&J EXEC SAYS CONFIDENT ABOUT DELIVERING A BILLION COVID-19 VACCINE DOSES IN 2022; TO GIVE FINANCIAL GUIDANCE ON VACCINE IN JAN - COMPANY BUSINESS REVIEW Further company coverage:

BRIEF-BBVA Plans To Proceed With Share Buy-Back "Unless Circumstances Change", Chairman says
https://www.reuters.com/article/brief-bbva-plans-to-proceed-with-share-b/brief-bbva-plans-to-proceed-with-share-buy-back-unless-circumstances-change-chairman-says-idUSS0N2R200E

Nov 18th, 2021 - Nov 18 (Reuters) - Chairman Of Spain’s BBVA, Carlos Torres: * SAYS HAVE TO WAIT IF BANK SUCCEEDS IN ITALY WITH RECENTLY LAUNCHED DIGITAL BANK BEFORE INVESTING IN OTHER MARKETS * CEO ONUR GENC SAYS “UNLESS CIRCUMSTANCES CHANGE IN A VERY SIGNIFICANT WAY” PLAN IS TO PROCEED WITH 3.5 BILLION EURO SHARE BUY-BACK Source text for Eikon: Further company coverage: (Reporting By Madrid Newsroom)

BRIEF-BBVA's Chairman Says New Dividend Policy Has Immediate Effect
https://www.reuters.com/article/brief-bbvas-chairman-says-new-dividend-p/brief-bbvas-chairman-says-new-dividend-policy-has-immediate-effect-idUSS0N2R200D

Nov 18th, 2021 - Nov 18 (Reuters) - Chairman Of Spain’s BBVA, Carlos Torres: * SAYS NEW DIVIDEND POLICY HAS IMMEDIATE EFFECT Source text for Eikon: Further company coverage: (Reporting By Madrid Newsroom)

BRIEF-BBVA's Chairman Says We Will Not Engage In M&A Activity Just To Rebalance Our Portfolio
https://www.reuters.com/article/brief-bbvas-chairman-says-we-will-not-en/brief-bbvas-chairman-says-we-will-not-engage-in-ma-activity-just-to-rebalance-our-portfolio-idUSS0N2R200B

Nov 18th, 2021 - Nov 18 (Reuters) - Chairman Of Spain’s BBVA, Carlos Torres: * SAYS ANY POTENTIAL TRANSACTION, INCLUDING IN M&A, HAS TO ADD VALUE TO SHAREHOLDERS * SAYS DEPENDING OUTCOME OF THE OFFER FOR TURKISH LENDER GARANTI, BANK COULD KEEP BUYING SHARES IN THE MARKET DEPENDING ON THE PRICE * SAYS WOULD BE PLEASED TO ACHIEVE 100% OF TURKISH LENDER GARANTI, BUT KEEPS OPTION TO BUY SHARES IN THE MARKET IF TAKE...

BRIEF-BBVA Will Launch First Tranche Of 3.5 Billion Euro Share Buy-Back Early Next Week
https://www.reuters.com/article/brief-bbva-will-launch-first-tranche-of/brief-bbva-will-launch-first-tranche-of-3-5-billion-euro-share-buy-back-early-next-week-idUSS0N2R200A

Nov 18th, 2021 - Nov 18 (Reuters) - Chairman Of Spain’s BBVA, Carlos Torres: * SAYS IT PLANS TO START FIRST TRANCHE OF APPROVED 3.5 BILLION EURO SHARE BUY-BACK PROGRAMME EARLY NEXT WEEK Source text for Eikon: Further company coverage: (Reporting By Madrid Newsroom)

BRIEF-BBVA's Chairman Says Worst Of Pandemic "Is Behind Us", Economic Growth Is Back
https://www.reuters.com/article/brief-bbvas-chairman-says-worst-of-pande/brief-bbvas-chairman-says-worst-of-pandemic-is-behind-us-economic-growth-is-back-idUSS0N2R2007

Nov 18th, 2021 - Nov 18 (Reuters) - Chairman Of Spain’s BBVA, Carlos Torres: * SAYS WORST OF THE COVID-19 PANDEMIC “IS BEHIND US” AND ECONOMIC GROWTH IS BACK Source text for Eikon: Further company coverage: (Reporting By Madrid Newsroom)

BRIEF-Gsk Showcases Progress From The Dreamm Clinical Trial Program In Multiple Myeloma
https://www.reuters.com/article/brief-gsk-showcases-progress-from-the-dr/brief-gsk-showcases-progress-from-the-dreamm-clinical-trial-program-in-multiple-myeloma-idUSFWN2S91C0

Nov 18th, 2021 - Nov 18 (Reuters) - GlaxoSmithKline PLC: * GSK SHOWCASES PROGRESS FROM THE DREAMM CLINICAL TRIAL PROGRAM IN MULTIPLE MYELOMA AT THE 2021 ASH ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Willis Towers To Revamp Board Following Activist Pressure - WSJ
https://www.reuters.com/article/brief-willis-towers-to-revamp-board-foll/brief-willis-towers-to-revamp-board-following-activist-pressure-wsj-idUSFWN2S91BF

Nov 18th, 2021 - Nov 18 (Reuters) - * WILLIS TOWERS TO REVAMP BOARD FOLLOWING ACTIVIST PRESSURE - WSJ * WILLIS TOWERS WILL REPLACE ITS CHAIRMAN AND THREE OTHER BOARD MEMBERS FOLLOWING TALKS WITH ACTIVIST INVESTOR ELLIOTT MANAGEMENT CORP - WSJ Further company coverage:

BRIEF-EMA Receives Application For Marketing Authorisation For Xevudy In Treating Patients With COVID-19
https://www.reuters.com/article/brief-ema-receives-application-for-marke/brief-ema-receives-application-for-marketing-authorisation-for-xevudy-in-treating-patients-with-covid-19-idUSFWN2S90GN

Nov 18th, 2021 - Nov 18 (Reuters) - GlaxoSmithKline PLC: * EMA: EMA RECEIVES APPLICATION FOR MARKETING AUTHORISATION FOR XEVUDY (SOTROVIMAB) FOR TREATING PATIENTS WITH COVID-19: 18/11/2021 * EMA: WILL ASSESS THE BENEFITS AND RISKS OF XEVUDY UNDER A REDUCED TIMELINE * EMA: XEVUDY INTENDED FOR TREATMENT OF ADULTS, ADOLESCENTS WITH COVID-19 WHO DO NOT REQUIRE SUPPLEMENTAL OXYGEN THERAPY, AT INCREASED RISK OF PROGR...